Therini Bio
PrivateLast Round
Series A
Extension
May 14, 2025
Total Funding Raised
$104.32M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Therini Bio operates in Healthcare & Life Sciences and is based in South San Francisco, California. Its latest recorded funding round was a Series A Extension round in May 2025.
Therini Bio is a biotechnology company developing fibrin-targeting immunotherapies to treat neuroinflammatory and retinal diseases driven by vascular dysfunction.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Therini Bio Comparables
Compare Therini Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NeuroTherapia, Inc. | 76% | |
| MindImmune Therapeutics, Inc. | 75% | |
| Alector | 74% |
For institutional investors. Book with your work email.
Therini Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | May 14, 2025 | ||||
| Series A | Apr 27, 2023 | ||||
| Grant | Sep 1, 2021 | ||||
| Seed | May 10, 2021 | ||||
| Seed | Feb 24, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Therini Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Apollo Ventures | Series A Extension |
| Dolby Family Ventures | Series A Extension, Series A, Seed |
| SV Health Investors | Series A Extension, Series A, Seed |
| NIH RADx | Grant |
| Blue Goose Capital | Series A Extension |
| National MS Society | Seed |
| The Foundation For A Better World | Series A Extension, Series A, Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 14, 2026
Monthly visitors increased 69% MoM to 1.4K.
- Jun 2, 2026
Grew 25% QoQ, from 12 to 15 employees.
For institutional investors. Book with your work email.
Therini Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Therini Bio's valuation, stock price, and market status.
Is Therini Bio a public or private company?
Therini Bio is a private company.
What is the current stock price of Therini Bio?
Therini Bio is a private company, so its shares have no public market price. Caplight tracks Therini Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Therini Bio worth (valuation)?
Valuation information for Therini Bio is not publicly available.
Can I buy Therini Bio stock?
Therini Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Therini Bio's last funding round?
Therini Bio's most recent funding round was Series A Extension on May 14, 2025.
Who are the main investors in Therini Bio?
Key investors in Therini Bio include Dolby Family Ventures, SV Health Investors, Angelini Ventures, Sanofi Ventures, Alzheimer's Drug Discovery Foundation.
Will Therini Bio IPO soon?
No public IPO plans have been announced for Therini Bio.
How can I track Therini Bio secondary market activity?
Caplight tracks bids, offers, and trades in Therini Bio's shares on secondary markets.